Lauren Collin, PA
Medical · Wethersfield, CTNPI 1568836773
Payments from drug & device makers
Across 104 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$389
- Jazz Pharmaceuticals Inc.$128
- Regeneron Healthcare Solutions, Inc.$112
- Inspire Medical Systems, Inc.$96
- Boehringer Ingelheim$93
- plus $238 from 7 others
What the payments were for
- Food & beverage$2,09099%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 60 | $1,047 |
| AstraZeneca | 16 | $389 |
| Jazz Pharmaceuticals Inc. | 6 | $128 |
| Regeneron Healthcare Solutions, Inc. | 5 | $112 |
| Inspire Medical Systems, Inc. | 1 | $96 |
| Boehringer Ingelheim | 4 | $93 |
| Verona Pharma, Inc. | 2 | $47 |
| Mylan Specialty L.p. | 3 | $44 |
| Insmed, Inc. | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Amgen | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- TEZSPIRE$116
How this compares
$2,104 in reported general payments places this provider in the 80th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 156 | $131,403 |
| TezspireTezepelumab-Ekko | 26 | $111,179 |
| Fasenra PenBenralizumab | 15 | $84,193 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $36,029 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $29,996 |
| Spiriva HandihalerTiotropium Bromide | 23 | $18,722 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $14,665 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $10,945 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,501 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,729 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $3,288 |
| Pulmicort FlexhalerBudesonide | 12 | $2,658 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,423 |
| Ventolin HfaAlbuterol Sulfate | 36 | $2,065 |
| Montelukast Sodium | 46 | $517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,047 | $172,344213 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Pulmicort Flexhaler | $389 | $153,59594 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $93 | $23,16536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 592 medical providers in Connecticut.
Other medical in Wethersfield
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Alyssa GreenleafSouthington$26K
- Mark VolpeSuffield$21K
- Josephine DiazSuffield$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.